Associate Professor Dipti Talaulikar is a Senior Consultant in Clinical and Laboratory Hematology at Canberra Hospital and Associate Professor at the Australian National University (ANU). She is also a long-standing member of Myeloma Australia’s Medical and Scientific Advisor Group, as well as other leading cancer trial and research groups. She is dedicated to improving patient wellbeing and has authored both national and international clinical practice guidelines that have had a significant impact on cancer patient care. She has also served as Principal Investigator and co-investigator of several lymphoma, leukemia and myeloma trials.
Dr. Talaulikar contributes to medical workforce development and advocacy for equity of access to diagnostic tests and blood cancer treatments through leadership roles in organizations such as Royal College of Pathologists of Australasia (RCPA), National Blood Authority and Myeloma Australia. She is recognized as a key opinion leader (KOL) and is regularly invited to participate in Advisory Boards of pharmaceutical companies to provide guidance into clinical development of drugs, feedback into trial protocols and insights into research opportunities.
Daniel (Yanhe) Wang, MD, PhD Head of Biostatistics, George Clinical Daniel is the Head of Biostatistics at George Clinical, MD and PhD of Fudan University, and he was an associate researcher at the Chinese CDC. He has nine publications and more than fifteen years’ work experience in biostatistics. Daniel has experience in leading, reviewing and performing oversight on hundreds of clinical trials from Phase I–IV in the therapeutic areas of oncology, immunology, cardiology, respiratory, neurology, endocrinology, nephrology, infectious diseases and medical devices. He also has experience as a physician and statistics method exploration. He is very familiar with every step of the clinical development process, from the study design to the end of the study and final statistical output/study report, as well as the SOPs in CRO, ICH/GCP, and the guidelines such as RECIST and CTCAE.
Hiddo Lambers Heerspink is affiliated with the Department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen, the Netherlands. He received his PhD from the medical faculty of the University Medical Center Groningen in 2008. He then worked as a post-doctoral fellow at The George Institute in Sydney, Australia where he investigated the effects of blood pressure lowering regimens on renal and cardiovascular outcomes in patients with renal impairment. Based on this work, he was awarded a young investigator grant and, subsequently in 2015, a consolidator investigator grant from the Dutch organization of scientific research.
Since 2010, Professor Heerspink has held a position as a Clinical Pharmacologist at the University Medical Center Groningen. He is currently Professor Clinical Trials and Personalized Medicine. His main research interests include optimizing treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease. His clinical research interest is to identify determinants of individual treatment responses and ways to optimize drug response in individual patients. To achieve these goals, he is involved in various international clinical trials and uses biomarkers and imaging techniques to unravel pathways and determinants of therapy response.
Mark Huffman is the Quentin D. Young Professor of Health Policy and Associate Professor of Preventive Medicine and Medicine-Cardiology at Northwestern University’s Feinberg School of Medicine and director of the Center for Global Cardiovascular Health within the Institute for Global Health at Northwestern. He has a secondary appointment as an Associate Professor of Food Policy at The George Institute for Global Health and Cardiovascular Medicine at the University of New South Wales, both in Sydney, Australia. He is a practicing cardiologist, researcher, and teacher interested in global cardiovascular health epidemiology, clinical trials, implementation science, health systems, and policy research and training. Mark also works across the spectrum of cardiovascular disease prevention in research on acute cardiovascular quality improvement, simplifying pharmacotherapy through fixed-dose combinations, programmatic implementation, and evaluation for large-scale hypertension control, monitoring and improving the USA and global food and medicine supply, and achieving tobacco endgame. His aim is to improve global cardiovascular health and health care, especially in low- and middle-income countries, and to bring lessons learned back home to the United States of America.
Professor Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials. She started the first Heart Failure with Preserved Ejection Fraction Programme and Women’s Heart Health Clinic in Singapore. She is the Programme Lead of the Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) – an A*STAR Biomedical Research Council-funded research platform; and principal investigator of an ongoing nation-wide heart failure study in Singapore (the Singapore Heart Failure Outcomes and Phenotypes [SHOP] study), a multinational Asian study of heart failure across 11 Asian countries (Asian Sudden Cardiac Death in Heart Failure [ASIAN-HF] study), as well as a multinational Asian registry of diabetes (Asian Diabetes Outcomes Registry [ADORE]) in collaboration with the American College of Cardiology’s Diabetes Collaborative Registry. She serves as a consultant on several global advisory boards for cardiovascular disease, as a member of the Executive Committees of global heart failure trials, and as an Associate Editor for Circulation and European Journal of Heart Failure.
Dr. Mikhail Kosiborod is a cardiologist, Vice President of Research at Saint Luke’s Health System, Director of Cardiometabolic Research and the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. He received training in clinical research, epidemiology and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine.
Dr. Kosiborod is an internationally recognized expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. He has authored and co-authored over 170 peer-reviewed publications, including scientific statements and position documents. He is involved in the leadership of numerous clinical trials and multi-center registries and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.
Candice Delcourt is a neurologist specializing in stroke medicine. She is a Senior Research Fellow at The George Institute in Sydney and the Hunter Stroke Service in Newcastle. She is a Senior Clinical Lecturer at the University of Sydney. She holds a clinical appointment at the Royal Prince Alfred Hospital.
She obtained her specialist medical qualification in Neurology from the University of Liege (Belgium) and additional qualifications in cerebro-vascular medicine from the University of Dijon (France) and in neurophysiology from the University of Lille (France).
She is an executive committee member of the Stroke Society of Australasia and the Australian Stroke Trial Network.
Working in the Professorial Advisory Unit of The George Institute, Mark is also a Professor of Medical Statistics in the Faculty of Medicine, UNSW Sydney, Professor of Statistics and Epidemiology at the University of Oxford, where he is an Oxford Martin Senior Fellow and Adjunct Professor of Epidemiology at Johns Hopkins University.
He is the author of 400+ peer-reviewed publications and two text-books on statistical methods in medical research, one of which had its third edition published in January 2014. In the five year period from January 2009 to December 2013 he published 161 (>40% of his total) peer-reviewed publications, including seven in The Lancet, two in NEJM and one in JAMA. Three of his papers have over a thousand citations.
Mark has led four major international studies and directed the analytical research on three landmark collaborative studies, worldwide. His work on cardiovascular risk scores formed the basis of national guidelines in Scotland, and his recent work on kidney disease was used to produce new staging criteria for this disease. His total career grant awards are over $93 million from 39 successful applications.
He also has extensive experience in student teaching, postgraduate supervision and mentoring including 14 PhD and 19 MSc students successfully completed. He has given training workshops in Korea and Thailand, and has taught at least 25 other research training courses.
Mark served on the governing council of the Institute of Statisticians and the Royal Statistical Society (RSS) and is currently a fellow of the RSS, the European Society of Cardiology, the New York Academy of Medicine and the Royal Society of Medicine.
He has wide experience of development aid work in Africa and Asia, having undertaken 25 missions for aid agencies, such as the WHO. He has also assessed grants for six national medical research councils (including NHMRC) and served on the editorial boards of seven international journals.
Stephen Jan is Head of the Health Economics and Process Evaluation Program at the George Institute for Global Health and Professor, Faculty of Medicine, UNSW Sydney.
He is an Honorary Professor at the University of Sydney, a Director of the Sax Institute and an Associate at both the Menzies Centre for Health Policy and the Poche Centre for Indigenous Health. He is a current NHMRC Principal Research Fellow and has previously held posts at the London School of Hygiene and Tropical Medicine and the Centre for Health Economics Research and Evaluation (CHERE) in Sydney. Stephen has over 20 years of experience in health economics, has published over 200 scientific articles and authored two textbooks in health economics.
He has worked closely with various governments of different levels, both in Australia (Commonwealth and State) and overseas, with international agencies such as the WHO and industry. His areas of expertise are economic evaluation, health financing, health sector priority setting, Indigenous and global health issues and the economics of chronic disease.
Laurent is a senior biostatistician with 20 years of experience in health research. He is Director of the Statistics Division at the George Institute for Global Health and Associate Professor, Faculty of Medicine, UNSW Sydney.
He is responsible for providing statistical services to the George Institute and its collaborators in Australia and globally. He holds a Master of Science in Statistics and Computer Science and a Master of Research in Public Health (Biostatistics). He is an accredited statistician by the Statistical Society of Australia (AStat).
John Chalmers AC FAA has an outstanding record in hypertension research, both fundamental and clinical. His groundbreaking research on the role of the brain in the development of hypertension led to his election to Fellowship of the Australian Academy of Science and helped establish Flinders University as a leading international centre in hypertension and neuroscience research.
His studies on the treatment of high blood pressure for the prevention of heart attack and stroke have changed the way patients are treated throughout the world. His work has been recognised through many awards including the Wellcome Medal, the RT Hall Prize of the Cardiac Society of Australia and New Zealand, The Zanchetti Lifetime Achievement Award of the European Society of Hypertension and the Volhard Medal of the International Society of Hypertension.
Professor Chalmers’ contribution to medical science has been acknowledged through the award of many Honorary Doctoral degrees and extensive appointments on national and international boards and advisory committees. He was appointed a Companion in the Order of Australia (AC) in 1991 and an Officer in the National Order of Merit of France in 2010.
John Chalmers remains an active researcher at The George Institute Australia, where he is a principal investigator on many research grants and chair of steering committees for major studies, mentors young clinical researchers from around the world, and continues to publish and lecture prolifically.
Dr. Wong is Renal Physician at the Royal North Shore hospital, Sydney, Australia. He is also a senior research fellow at the George Institute of Global Health and holds a Senior Lecturer position, Faculty of Medicine, UNSW Sydney. His PhD entitled “Novel therapeutic options in models of nephropathy” was awarded in 2011.
His main area of research is in understanding the pathomechanisms of kidney tubulointerstitial fibrosis and biomarkers in predicting progression of chronic kidney disease particularly in diabetic kidney disease.
Dr. Wong has worked on kidney injury molecule-1, transforming growth factor-β1, bone morphogenetic protein-7, Farnesoid X receptor and novel anti-fibrotic and anti-inflammatory agents in extracellular matrix deposition in human proximal tubular cells and in vivo model of fibrosis.
His is also passionate in translation medicine and is involved in the post hoc analyses of the IDEAL study and currently involved in multicentre international trials at the George Institute including TESTING and SONAR study.
Martin holds positions as Associate Professor, Faculty of Medicine, UNSW Sydney, Associate Professor of Medicine at Concord Hospital Clinical School (part of the Sydney Medical School), Director of the Renal and Metabolic Division in the George Institute and a clinical nephrologist in the Renal Dept. at Concord Repatriation and General Hospital. He works extensively in the ANZ Society of Nephrology in renal guidelines and clinical policy.
Martin’s research interests include large scale clinical trials to explore ways to improve the outcomes of patients with kidney disease (esp. in the setting of acute kidney injury), extending the follow up of such clinical trials to understand the long-term effects of treatments, measurement of health systems and the means of applying research evidence into practice.
Anthony Rodgers is a Professor of Global Health at The George Institute. After graduating in medicine in the United Kingdom he trained in epidemiology and public health in New Zealand. He was the Principal Author of the 2002 World Health Report, the main annual publication for WHO.
Since 2003 he has led a public-private partnership developing an affordable four-in-one cardiovascular combination pill (‘polypill’), with a clinical trial program in economically developed and developing countries. His current work aims to foster similar developments designed to be ‘fit for purpose’ in low income settings.
Kazem Rahimi is the James Martin Senior Fellow in Essential Healthcare at the University of Oxford and Honorary Consultant Cardiologist at the John Radcliffe Hospital, Oxford. As the Deputy Director of The George Institute UK he leads the Essential Healthcare Programme, which aims to find practical and affordable solutions for the global health priorities of the world’s largest emerging economies, as well as the priorities of vulnerable or disadvantaged populations in established economies.
He graduated in medicine from the University of Leipzig in Germany with postgraduate training in cardiology and health services research in Leipzig, London and Oxford. Prior to joining the George Institute, in 2010, he was a Research Fellow at Oxford’s Clinical Trial Service and Epidemiological Studies Unit. His research interests include service delivery innovation in chronic disease prevention and management, large-scale complex intervention studies, and data-driven electronic decision support systems.
Professor Vivekanand Jha is the Executive Director, The George Institute for Global Health, India, and James Martin Fellow at The George Institute for Global Health at the University of Oxford.
Prior to joining The George Institute, he was Professor of Nephrology and Head, Department of Translational Regenerative Medicine and Officer-In-Charge, Medical Education and Research Cell at the Postgraduate Institute of Medical Education and Research in Chandigarh, India. Vivek serves on the international advisory boards of several organizations, including membership of the WHO Expert Advisory Panel on Human Cell, Tissue and Organ Transplantation, and the executive committee of the International Society of Nephrology.
He is on the EMJ Editorial Board, counselor of the International Society of Nephrology, a member of the education committees for the International Transplantation Society and International Society of Peritoneal Dialysis. He is a physician with a specialization in the area of kidney diseases and he focuses on emerging public health threats globally and in India. He is particularly interested in using multi-disciplinary approaches and innovation to address the major challenge posed to humanity by non-communicable diseases.
Professor John A Myburgh AO, is Professor of Intensive Care Medicine, UNSW Sydney; Director of the Division of Critical Care and Trauma at the George Institute for International Health and Senior Intensive Care Physician at the St George Hospital, Sydney. He holds honorary Professorial appointments at the University of Sydney and Monash University School of Public Health and Preventive Medicine.
He has an extensive research track record over 25 years and is regarded as a national and international expert in catecholamine neurophysiology and pharmacology, trials of clinical management of traumatic brain injury, fluid resuscitation and in the development and co-ordination of over 35 clinical trials in Intensive Care Medicine.
He is a Foundation Member and Past-Chairman of the Australian and New Zealand Intensive Care Society Clinical Trials Group. He was instrumental in the establishment of the Australian and New Zealand Intensive Care Research Centre at the Monash University School of Public Health and Preventive Medicine. In addition to his research profile, he has made a substantive contribution to education in Intensive Care Medicine, both at undergraduate and postgraduate levels over the last 25 years. He was instrumental in establishing the College of Intensive Care Medicine, serving as a Fellowship examiner for twelve years, on the Board for ten years and as the first elected President from 2010-2012.
In June 2014, he was made an Officer of the Order of Australia (AO) for distinguished service to medicine as an intensive care medical practitioner, educator and researcher, and as an international innovator in patient management.
Simon Finfer is a Professorial Fellow in the Critical Care and Trauma Division at The George Institute for Global Health. He is a practicing critical care physician with an appointment as a Senior Staff Specialist at Royal North Shore Hospital and Director of Intensive Care at the Sydney Adventist Hospital, the largest not-for-profit hospital in New South Wales.
Simon holds a Professor appointment at the University of New South Wales, and a Clinical Professor at the University of Sydney. He is a past-Chair of the Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. He chairs the Council of the International Sepsis Forum, and is a member (Treasurer) of the Global Sepsis Alliance Executive. Simon is a member of the World Sepsis Day Steering Committee and recently co-chaired the 1st World Sepsis Congress, a two-day free online congress that attracted 14,000 registrants.
His postgraduate qualifications include Fellowships of the Royal Colleges of Physicians, the Royal College of Anaesthetists and the College of Intensive Care Medicine. He was elected to the ANZICS Honour Roll in 2011 and in 2012 he was awarded an honorary doctorate (Doctor of Medicine) by The Friedrich-Schiller University in Germany, an honour awarded once every 10 years. He is a Fellow of the Australian Academy of Health and Medical Sciences.
Simon’s major research interest is the design and conduct of large scale randomized controlled trials in critical care. Simon is active in forging major international research collaborations that have conducted large scale clinical trials and epidemiological research to improve the treatment of critically ill and injured patients. He has published over 150 peer reviewed papers, many in the most prestigious journal in the world. He is frequently invited to lecture at major international conferences.
Simon is an Editor of The Oxford Textbook of Critical Care (2nd Ed.), the Critical Care Section Editor for The Oxford Textbook of Medicine (6th Ed.), and was a guest editor for The New England Journal of Medicine from 2012 – 2014.
Professor Craig Anderson is Professor of Neurology and Epidemiology, Faculty of Medicine, UNSW Sydney, and is in part-time clinical practice as a neurologist at Royal Prince Alfred Hospital, Sydney, Australia. He is Executive Director of The George Institute, China and based with the team at Peking University Health Science Center in Beijing, China.
Craig holds specialist qualifications in clinical neurology and geriatrics, a PhD in medicine and epidemiology from The University of Western Australia and is a Senior Principal Research Fellow of the National Health and Medical Research Council (NHMRC) of Australia. He is a past President of the Asia-Pacific Stroke Organization and the Stroke Society of Australasia and is a member of several specialist societies and an editor for the Cochrane Stroke Group. He has published widely on the clinical and epidemiological aspects of stroke, cardiovascular disease and aged care, and has led several large-scale investigator-initiated epidemiological and clinical trials that have had a major influence on clinical practice guidelines for stroke treatment and prevention.
Christine Jenkins is Head of the Respiratory Group at The George Institute for Global Health; Senior Staff Specialist in Thoracic Medicine at Concord Hospital, Sydney; Clinical Professor and Head of Respiratory Discipline at the University of Sydney; and Professor of Respiratory Medicine at UNSW Sydney.
Christine has been principal investigator and has led many investigator-initiated and competitively funded clinical trials in airways disease. She has had major roles in advocacy and leadership for lung health in Australia, chairing the National Asthma Campaign, the Federal Government’s National Asthma Advisory Group and many local and international guidelines and implementation initiatives to enhance resources, skills, capacity and clinical outcomes in airways disease. She was president of the Thoracic Society of Australia and New Zealand from 2007 – 2009.
Christine is an active clinician and teaches and supervises medical students, advanced trainees and post graduate students. Her area of research interest is the clinical management of airways disease and patient reported outcomes in response to therapeutic interventions, and she is currently implementing trials in asthma and COPD management and pulmonary rehabilitation in Australia and Asia. Christine has written two books on asthma, one for medical students and one for patients, their families and careers. In 2002 she was made a Member of the Order of Australia for recognition of service to respiratory medicine as a physician, administrator and educator, especially in the field of asthma education.
She is on the Board of the Lung Foundation Australia and is a member of the Thoracic Society of Australia and New Zealand, the American Thoracic Society, European Respiratory Society and the Asian Pacific Society of Respirology.
A/Prof Meg Jardine is a clinician researcher developing a program of research exploring the cardiovascular and other complications of chronic kidney disease and diabetes.
Dr. Jardine has worked as a Nephrologist in both the public and private sectors, where she directly manages chronic kidney disease and diabetes and their consequences for patients.
She is currently Deputy Director of the Renal & Metabolic Division at the George Institute for Global Health; Associate Professor at the Faculty of Medicine, UNSW Sydney; and holds an NHMRC Career Development Fellowship. She has presented her work in late breaking and prize sessions of the World Congress of Nephrology and the Australasian Nephrology conference and has published in high impact journals. Dr. Jardine is collaborating on the development and delivery of other national and international trials investigating methods to mitigate the excess burden of cardiovascular disease and is Chair of the Australasian Kidney Trials Network Haemodialysis Working Group.
Bruce Neal is a Senior Director at The George Institute for Global Health; Professor of Medicine, UNSW Sydney; and Chair of the Australian Division of World Action on Salt and Health.
Dr. Neal is a UK-trained physician who has 20 years research experience in the clinical, epidemiological, and public health fields with a focus on heart disease, stroke and diabetes. Bruce has a longstanding interest in the environmental determinants of high blood pressure and the potential for changes in the food supply to deliver health gains. His work has been characterized by its focus on collaboration, quantitation, translation and impact. He holds professorial appointments at UNSW Sydney, Imperial College London, Flinders University in South Australia, an honorary appointment at the University of Sydney and chairs the Australian Division of World Action on Salt and Health. He has published some 300 scientific papers and in 2016 was identified by Thomson Reuters as one of ‘The World’s Most Influential Scientific Minds’, an acknowledgement provided to just 3000 researchers across all disciplines, worldwide. He has particular expertise in salt reduction but also a broader knowledge of food policy issues related to sugars, fats, portion size and food labelling.
Primary research interests include breast cancer, supportive care and developmental therapeutics. Recently involved with genomic profiling of advanced cancer. Interested in visionary approaches to clinical research and oncology science. Divides his time between individual patients in the clinic and conducting clinical research trials and programmatic development.
Dr. Ari VanderWalde is an internationally recognized researcher providing expertise in oncology clinical trials with a focus on immune therapies in solid tumors and melanoma. He has worked in the pharmaceutical industry helping lead the approval of a new compound in Melanoma. Along with this experience, he also works at a premier cancer research institute and as a scientific expert in a global CRO specializing in oncology.
In addition, Dr. VanderWalde has collaborated and participated on advisory boards with many of the nation’s thought leaders and top experts in the field and holds a dual appointment with the University of Tennessee Health Science Center as Associate Vice Chancellor of Research and Assistant Professor, Hematology/Oncology. He is involved in research that can improve treatment for cancer patients by targeting therapy in a more personalized fashion based on immune markers and aberrations in cancer genetics.
Vlado Perkovic is Dean of Medicine and Scientia Professor at UNSW, a Professorial Fellow at The George Institute, Australia, and a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is in clinical trials and epidemiology, in particular in preventing the progression of kidney disease and its complications. He leads several major international clinical trials, and serves on the Steering Committees of several others. He has been involved in developing Australian and global guidelines in kidney disease, cardiovascular risk assessment and blood pressure management.
Vlado holds a Doctor of Philosophy from the University of Melbourne and completed his undergraduate training at The Royal Melbourne Hospital. He is Chair of the International Society of Nephrology Action for Clinical Trials (ISN-ACT) group; and is a Fellow of the Royal Australasian College of Physicians, of the Australian Academy of Health and Medical Sciences and of the American Society of Nephrology
David is Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid lowering regimens, calcimimetics and sodium glucose cotransporter 2 inhibitors in patients chronic kidney disease. He has developed clinical practice guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO), of which he is currently Co-Chair. He is Past President of the UK Renal Association, past chair of the UK Renal Registry and currently National Institute for Health Research (NIHR) National Specialty Lead for Nephrology.
Dr. Roberto Pecoits-Filho is currently a Senior Research Scientist, Arbor Research Collaborative for Health in the USA and a full professor at the School of Medicine, Catholic University of Paraná, where he was the director of the PhD and Masters Programs in Health Sciences, Chief of Nephrology and co-founder of the Academic Clinical Research Organization (ACRO) EPICENTER (Center of Epidemiology and Clinical Research) and PUCTrials in the same institution. Dr. Pecoits-Filho received his M.D. degree in 1993, trained in Internal Medicine and Nephrology in Curitiba and completed his nephrology fellowship at the University of Missouri, Columbia in 1997-98. He received a Ph.D. from the University of São Paulo and thereafter went to Sweden as a visiting scholar at the Karolinska Institutet from 1999 to 2002. Dr. Pecoits-Filho was a visiting fellow at the George Institute in Sydney in 2017.
Dr. Pecoits-Filho has been involved in clinical research since 2003, and was a principal investigator of 17 multicentric clinical trials. He is a National Leader of several ongoing clinical trials such as Credence, Olympus, and CKD DAPA and sits at the steering committee of the observational studies CKDOPPS, MONDO and BRAZPD. He was the Chair of the Steering Committee of the STARCH, SALTED and HDFit multicentric trials in Brazil that were coordinated by the ACRO PUCTrials. In those trials, he played an active role in study design, implementation, coordination, event adjudication, data management and led the data monitoring safety board (DMSB) for STARCH and HDFit.
Dr. Pecoits-Filho is part of the Editorial Board of American Journal of Kidney Diseases, Peritoneal Dialysis International, and Blood Purification. During his career, he has published his research in over 240 papers in international indexed journals, and lectured in more than 40 countries around the world.
In the past he was scientific director of the Brazilian Society of Nephrology and vice president of the Latin American Society of Nephrology and Hypertension. He was awarded the Young Nephrology Leader Award of the Global Kidney Academy, the Maher Award of the ISPD, Paraná State Award for Science and Technology and was an Education Ambassador of the ISN. Currently, he is a Councilor of the International Society of Nephrology. He is also a member of the Executive Committee of KDIGO and part of the Core Group of ISN’s Advancing Clinical Trials (ACT) Initiative, and the International Network of Chronic Kidney Disease Cohort Studies (iNET-CKD).
Johan Sundström is a Professor of Epidemiology at Uppsala University, Conjoint Professor at The George Institute of Global Health, University of New South Wales and a clinical specialist in internal medicine and cardiology at the Department of Cardiology of Uppsala University Hospital. He heads the university’s Clinical Epidemiology research group. Johan’s passion is using big data to create value for patients and populations. He is devoted to developing methods for risk estimation, treatment decisions, and evaluation of treatment effects, risks and costs. In addition to creating data sources such as clinical trials and cohorts, he develops methods for emerging ones such as electronic health records and digital patient-generated data.
He has mainly contributed to the understanding of cardiovascular disease and its risk factors, with a focus on high blood pressure. His work is cited in several international cardiovascular prevention and hypertension guidelines. After a productive post-doctoral year at the Framingham Heart Study, he has mainly investigated the causes and consequences of hypertension. During a most valuable year spent at the George Institute for Global Health at Sydney University, he initiated a series of studies in the Blood Pressure Lowering Treatment Trialists’ Collaboration investigating optimal targeting of blood pressure-lowering treatment.
Board certified in both hematology and oncology. Has a research interest in cancers of the blood and blood-forming tissues as well as solid tumors, such as those seen in bladder cancer. Conducts research in exploring the latest advances colorectal cancer treatment. Offers individualized care to patients with focus on multi-modal treatment regimens.
Dr. Adrian Liew is a Senior Consultant Nephrologist and Director of The Kidney and Transplant Practice at Mount Elizabeth Novena Hospital in Singapore. He was the founding Chief of Nephrology at the Department of Renal Medicine in Tan Tock Seng Hospital, Singapore, and was an Associate Professor of Medicine, in charge of the Renal Medicine Curriculum and Clinical OSCEs, with the LKC School of Medicine at the Imperial College London-Nanyang Technological University before moving to his current role.
He is a member of the Executive Committee and elected council member of the International Society of Nephrology (ISN) and chairs the ISN Oceania-Southeast Asia Regional Board and the ISN Renal Disaster Preparedness Working Group. He is also the elected secretary and executive of the International Society for Peritoneal Dialysis and is appointed a member of the KDIGO Guideline working groups for glomerular diseases as well as diabetic kidney disease. His research interests are in glomerular diseases, peritoneal dialysis and diabetic kidney diseases, and is the national leader and steering committee member for various multi-centre clinical trials.
Alta (Aletta E.) Schutte, Ph.D. is Principal Theme Lead of Cardiac, Vascular and Metabolic Medicine in the Faculty of Medicine at the University of New South Wales, Sydney, Australia and Professorial Fellow at the George Institute for Global Health. She has extensive experience in working in the field of hypertension and cardiovascular disease within Africa as well as part of global projects. She is also Extraordinary Professor at the Hypertension in Africa Research Team (HART) at the North-West University in South Africa where she served as Unit Director of Medical Research Council Extramural Unit for Hypertension and Cardiovascular Disease.
She has a particular interest in the early detection, prevention and treatment of hypertension and cardiovascular disease in low resource settings and has led several multidisciplinary projects in this field, including biomarker discovery, early vascular aging and polyomics. Alta has published more than 300 papers and is involved in numerous international consortia, such as the Global Burden of Disease study (Washington DC), the NCD Risk Factor Collaboration (London), May Measurement Month initiative of the International Society of Hypertension, and was invited author of the Lancet Commission of Hypertension. She is the Past President of the Southern African Hypertension Society and President of the International Society of Hypertension (ISH).
Specializes in offering comprehensive care including advanced genomic and immunotherapy treatments to women with metastatic breast cancer. Advises patients on participating in clinical trials for leading-edge treatments. Emphasizes the importance of in-depth communication with patients taking a fully holistic approach to their treatment options.